MSC Extracellular Vesicle Isolation for Stronger Angiogenesis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing mesenchymal stem cell-derived extracellular vesicles exhibit weak and insufficient angiogenesis action for therapeutic applications.

Innovation Solution

The use of a method involving a substance with affinity for phosphatidylserine (PS) or stimulation with growth factors to isolate and produce extracellular vesicles from mesenchymal stem cells, enhancing their angiogenesis potential.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If ultracentrifugal method is used to acquire extracellular vesicles from mesenchymal stem cells, then extracellular vesicles can be obtained, but the angiogenesis action is weak and insufficient for industrial use

Engineering Contradiction:

Improveangiogenesis actionVSAvoidindustrial usability

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the isolation method parameter from ultracentrifugal method to phosphatidylserine affinity method, and introduces growth factor stimulation as a new parameter, which together significantly enhance the angiogenesis action of extracellular vesicles to meet industrial requirements

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies preliminary action by stimulating mesenchymal stem cells with growth factors before extracellular vesicle isolation, which pre-activates the cells to produce extracellular vesicles with enhanced angiogenesis potential, thereby improving the therapeutic effect

Inventive Principle:

Principle #10Preliminary action

2Reliability

If conventional extracellular vesicle isolation methods are used, then isolation can be performed, but the therapeutic effect is insufficient

Engineering Contradiction:

Improvetherapeutic effectVSAvoidisolation method complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses phosphatidylserine affinity substances as an intermediary to isolate extracellular vesicles, which specifically bind to phosphatidylserine on the vesicle surface, enabling efficient separation and concentration of bioactive extracellular vesicles with enhanced therapeutic effect

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the isolation approach by combining phosphatidylserine affinity method with growth factor stimulation, transforming conventional isolation into a method that produces extracellular vesicles with significantly improved therapeutic efficacy

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The resulting extracellular vesicles demonstrate a higher therapeutic effect in inducing angiogenesis, promoting tissue and organ regeneration.

Implementation Method 1

a method of using a substance that contains an extracellular vesicle having an affinity for phosphatidylserine

Methodology Applied

Scientific EffectAffinity binding: Adsorption

Data Source

PatentUS12533381B2Angiogenesis agent and method of producing extracellular vesicle having angiogenesis action

Publication Date: 2026.01.27 FUJIFILM WAKO PURE CHEMICAL CORP

AI summary

The present invention relates to the angiogenesis agent containing a mesenchymal stem cell-derived extracellular vesicle, as an active ingredient, in which an extracellular vesicle is obtained by a method of using a substance that contains an extracellular vesicle having an affinity for phosphatidylserine, or/and an extracellular vesicle is derived from a mesenchymal stem cell stimulated with a growth factor, and relates to a method of producing an extracellular vesicle as the angiogenesis agent.